Search

The Coronavirus Disease 2019 (COVID-19) can affect mental health in different ways. There is little research about psychiatric complications in hospitalized patients with COVID-19. The aim of the study was to describe the psychiatric clinical profile and pharmacological interactions in COVID-19 inpatients referred to a Consultation-Liaison Psychiatry (CLP) unit. This is a cross-sectional study, carried out at a tertiary hospital in Spain, in inpatients admitted because of COVID-19 and referred to our CLP Unit from March 17,2020 to April 28,2020. Clinical data were extracted from electronic medical records. The patients were divided in three groups depending on psychiatric diagnosis: delirium, severe mental illness (SMI) and non-severe mental illness (NSMI). Of 71 patients included (median [ICR] age 64 [54–73] years; 70.4% male), 35.2% had a delirium, 18.3% had a SMI, and 46.5% had a NSMI. Compared to patients with delirium and NSMI, patients with SMI were younger, more likely to be institutionalized and were administered less anti-COVID19 drugs. Mortality was higher among patients with delirium (21.7%) than those with SMI (0%) or NSMI (9.45%). The rate of side effects due to interactions between anti-COVID19 and psychiatric drugs was low, mainly drowsiness (4.3%) and borderline QTc prolongation (1.5%). Patients affected by SMI were more often undertreated for COVID-19. However, the rate of interactions was very low, and avoidable with a proper evaluation and drug-dose adjustment. Half of the patients with SMI were institutionalized, suggesting that living conditions in residential facilities could make them more vulnerable to infection.

Resumen Introduccion Las diferencias de genero en la asistencia a consultas por trastorno delirante han sido escasamente estudiadas. Ademas, el trastorno delirante es tradicionalmente considerado como un trastorno resistente al tratamiento. Material y metodos Se llevo a cabo un estudio retrospectivo longitudinal que incluyo 78 pacientes con trastorno delirante (DSM- IV -TR) que ingresaron consecutivamente en nuestro centro en un periodo de 10 anos. Se realizo un seguimiento de los pacientes durante un ano con el objetivo de describir variables demograficas y clinicas y comparar la efectividad terapeutica. En este estudio, debido a su naturaleza no intervencionista, se realizo un analisis de las medidas de efectividad indirecta. La muestra se dividio en 3 grupos segun el tratamiento antipsicotico recibido en el primer ingreso. Resultados Veintitres pacientes recibieron risperidona inyectable de accion prolongada (RILD), 30 risperidona oral y 25 otros antipsicoticos atipicos orales. Las mujeres con trastorno delirante presentaron un inicio mas tardio del trastorno y requirieron un mayor tiempo de hospitalizacion. No se encontraron diferencias estadisticamente significativas entre los 3 grupos de tratamiento con respecto a los datos demograficos, al funcionamiento social y personal, asi como a la psicopatologia en el ingreso. En el seguimiento durante un ano el grupo RILD mostro un mayor porcentaje de permanencia al final del periodo evaluado. Ademas, el grupo RILD requirio con menor frecuencia un tratamiento con antidepresivos y benzodiazepinas. Conclusiones Concluimos que el tratamiento con RILD podria disminuir las perdidas en el seguimiento del trastorno delirante en comparacion con otros antipsicoticos atipicos.